KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Zimmer Biomet Holdings (ZBH) EBIT (2016 - 2026)

Zimmer Biomet Holdings has reported EBIT over the past 18 years, most recently at $373.2 million for Q1 2026.

  • For Q1 2026, EBIT rose 27.68% year-over-year to $373.2 million; the TTM value through Mar 2026 reached $1.2 billion, down 10.14%, while the annual FY2025 figure was $1.1 billion, 14.59% down from the prior year.
  • EBIT for Q1 2026 was $373.2 million at Zimmer Biomet Holdings, up from $154.5 million in the prior quarter.
  • Over five years, EBIT peaked at $389.0 million in Q4 2024 and troughed at -$28.3 million in Q4 2022.
  • A 5-year average of $278.3 million and a median of $292.3 million in 2025 define the central range for EBIT.
  • On a YoY basis, EBIT climbed as much as 2775.36% in 2022 and fell as far as 121.15% in 2022.
  • Year by year, EBIT stood at -$28.3 million in 2022, then surged by 1351.59% to $354.2 million in 2023, then rose by 9.82% to $389.0 million in 2024, then tumbled by 60.28% to $154.5 million in 2025, then surged by 141.55% to $373.2 million in 2026.
  • Business Quant data shows EBIT for ZBH at $373.2 million in Q1 2026, $154.5 million in Q4 2025, and $351.3 million in Q3 2025.